How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,894 results for

Atopic Dermatitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness

Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness Pimecrolimus (...) for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness Published on: September 25, 2017 Project Number: RC0919-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of pimecrolimus for the treatment of adults with atopic dermatitis? What is the clinical effectiveness of pimecrolimus for the treatment of adults with seborrheic dermatitis? What

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V

Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dupilumab (atopische Dermatitis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 February 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-63 (...) Dupilumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-63 Version 1.0 Dupilumab (atopic dermatitis) 27 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 1 December

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

3. Atopic dermatitis

Atopic dermatitis Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

4. Dupilumab (Dupixent) in adults with atopic dermatitis

Dupilumab (Dupixent) in adults with atopic dermatitis Prescrire IN ENGLISH - Spotlight ''Dupilumab (Dupixent°) in adults with atopic dermatitis'', 1 May 2019 {1} {1} {1} | | > > > Dupilumab (Dupixent°) in adults with atopic dermatitis Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the May issue of Prescrire International: Dupilumab (Dupixent (...) °) in adults with atopic dermatitis FREE DOWNLOAD Dupilumab (Dupixent°), a monoclonal antibody, is an option for very troublesome eczema after failure of ciclosporin. Full text available for free download. Summary Atopic dermatitis (also called atopic eczema) is a chronic relapsing-remitting inflammatory skin condition. The severity of cutaneous symptoms and their impact on daily life vary greatly from one patient to another. Dupilumab (Dupixent°, Sanofi Aventis) is a monoclonal antibody directed against

2019 Prescrire

5. Emollient Treatments for Atopic Dermatitis: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Emollient Treatments for Atopic Dermatitis: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Emollient Treatments for Atopic Dermatitis: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Emollient Treatments for Atopic Dermatitis: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Emollient Treatments for Atopic Dermatitis: A Review of Clinical Effectiveness, Cost-Effectiveness (...) , and Guidelines Last updated: January 14, 2019 Project Number: RC1056-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of emollient treatments for the management of atopic dermatitis? What is the cost-effectiveness of emollient treatments for management of atopic dermatitis? What are the evidence-based clinical practice guidelines for the use of emollient treatments in the management of atopic dermatitis? Key

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Dupilumab for treating moderate to severe atopic dermatitis

Dupilumab for treating moderate to severe atopic dermatitis Dupilumab for treating moder Dupilumab for treating moderate to ate to se sev vere atopic dermatitis ere atopic dermatitis T echnology appraisal guidance Published: 1 August 2018 nice.org.uk/guidance/ta534 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Dupilumab for treating moderate to severe atopic dermatitis (TA534) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about dupilumab 6 3

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

8. Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: The Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS). (PubMed)

Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: The Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS). Atopic dermatitis (AD) is a chronic, relapsing skin condition, with signs and symptoms that impact patients' lives and are best measured from the patient perspective. Therefore, there is a need for AD-specific questionnaires that are consistent with Food (...) harmonized and used to construct two draft PRO questionnaires: the Atopic Dermatitis Symptom Scale (ADerm-SS; 11 items) and the Atopic Dermatitis Impact Scale (ADerm-IS; 10 items). The content validity and questionnaire content were evaluated via qualitative concept elicitation/cognitive debriefing interviews with adult patients with moderate to severe AD.From the literature (N = 13 articles), 13 sign and symptom and 43 impact concepts were identified, while 21 sign and symptom and 48 impacts were

Full Text available with Trip Pro

2018 Current medical research and opinion

9. Eucrisa - crisaborole - atopic dermatitis

Eucrisa - crisaborole - atopic dermatitis crisaborole | CADTH.ca Find the information you need crisaborole crisaborole Last Updated: April 18, 2019 Result type: Reports Project Number: SR0570-000 Product Line: Generic Name: crisaborole Brand Name: Eucrisa Manufacturer: Pfizer Canada Inc. Indications: atopic dermatitis Manufacturer Requested Reimbursement Criteria 1 : For treatment of mild to moderate atopic dermatitis in patients 2 years of age and older who have failed or are intolerant

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

10. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. (PubMed)

European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the treatment of pregnant or lactating women and for adults planning to have a child are often lacking (...) . This position paper from the European Task force on Atopic Dermatitis (ETFAD) is based on up-to-date scientific literature on treating pregnant and lactating women as wells as adults with AD planning to have a child. It is based on the expert opinions of members of the ETFAD and on existing safety data on the proposed treatments, many of which are derived from patients with other inflammatory diseases or from transplantation medicine. For treating future parents, as well as pregnant and lactating women

2019 Journal of the European Academy of Dermatology and Venereology

11. Increasing severity of atopic dermatitis is associated with a negative impact on work productivity among adults with atopic dermatitis in France, Germany, the UK and the US. (PubMed)

Increasing severity of atopic dermatitis is associated with a negative impact on work productivity among adults with atopic dermatitis in France, Germany, the UK and the US. Atopic dermatitis (AD) is associated with high disease burden, with a significant physical and social impact. However, the association between disease severity and burden of disease, with work productivity and daily activities being one aspect, has not been well characterized.To investigate the impact of disease severity (...) on work productivity and daily activities among adults with AD in Europe (France, Germany and the UK) and the US.The survey panel participants for this cross-sectional internet-based survey on AD were sourced from the population-based National Health and Wellness Survey (NHWS) (Europe 2016, US 2015 and 2016). AD severity was determined by the PO-SCORAD (Patient-Oriented SCORing-Atopic Dermatitis). Work productivity and work activity impairment were assessed using the Work Productivity and Activity

2019 British Journal of Dermatology

12. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. (PubMed)

Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Background: Atopic dermatitis (AD) profoundly affects quality of life (QoL). Dupilumab significantly improves clinical outcomes, is well tolerated, and approved to treat inadequately controlled moderate-to-severe AD in adults; however, its effect

Full Text available with Trip Pro

2019 Journal of Dermatological Treatment Controlled trial quality: uncertain

13. Dupixent - dupilumab - atopic dermatitis

Dupixent - dupilumab - atopic dermatitis dupilumab | CADTH.ca Find the information you need dupilumab dupilumab Last Updated: July 10, 2018 Result type: Reports Project Number: SR0533-000 Product Line: Generic Name: dupilumab Brand Name: Dupixent Manufacturer: Sanofi-Genzyme Indications: atopic dermatitis Submission Type: New Project Status: Complete Biosimilar: No Date Recommendation Issued: June 27, 2018 Recommendation Type: Do not reimburse Fee Schedule: Schedule A Key Milestones 2 Call

2017 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

14. ASCIA Guide: Stepwise management of eczema (atopic dermatitis) management

ASCIA Guide: Stepwise management of eczema (atopic dermatitis) management INFECTIONS: Use times each day – dose for days See your doctor or nurse practitioner if eczema does not improve or if unwell with a fever OTHER TREATMENTS: TRIGGERS: Avoid or minimise exposure to triggers and irritants where possible, such as soap or perfumed products, overheating/over dressing or exposure to prickly fabrics www.allergy.org.au Stepwise management of eczema (atopic dermatitis) GUIDE © ASCIA 2018. ASCIA

2018 Australasian Society of Clinical Immunology and Allergy

15. Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value

Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value ©Institute for Clinical and Economic Review, 2017 Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value Final Evidence Report and Meeting Summary June 8, 2017 Prepared for ©Institute for Clinical and Economic Review, 2017 Page i Final Evidence Report – Atopic Dermatitis ICER Staff University of Washington School of Pharmacy Modeling Group David M. Rind, MD, MSc Chief Medical Officer, Institute (...) -effectiveness model, and the resulting ICER reports do not necessarily represent the views of the UW. DATE OF PUBLICATION: June 8, 2017 We would also like to thank Patricia Synnott, Matt Seidner, and Noah Mwandha for their contributions to this report. ©Institute for Clinical and Economic Review, 2017 Page ii Final Evidence Report – Atopic Dermatitis Return to Table of Contents About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates

2017 California Technology Assessment Forum

16. Atopic Dermatitis - Guidelines for Prescribing Topical Corticosteroids

Atopic Dermatitis - Guidelines for Prescribing Topical Corticosteroids Atopic Dermatitis - Guidelines for Prescribing Topical Corticosteroids - medSask Home - College of Pharmacy and Nutrition - University of Saskatchewan Toggle Menu Search the U of S Search Atopic Dermatitis - Guidelines for Prescribing Topical Corticosteroids Chronic, recurring, inflammatory disorder of the skin. Often referred to as eczema, but they are not interchangeable terms: Eczema is a group of skin conditions, which (...) atopic dermatitis is a part of. Eczema is a non-specific inflammatory skin reaction. Atopic dermatis is a type of eczema, usually considered the most severe and long lasting. Other types of eczema include contact dermatitis or seborrheic dermatitis. Once thought to be an allergic disorder, but there is now little support for this theory of pathogenesis. Typically, first appears in early childhood (i.e. the first year of life) and subsides with advancing age. Caused by a combination of skin barrier

Full Text available with Trip Pro

2017 medSask

17. Atopic Dermatitis in America Study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. (PubMed)

Atopic Dermatitis in America Study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. Population-based estimates on the prevalence of atopic dermatitis in adults vary widely. The objectives of this study were to determine the prevalence of atopic dermatitis in the population of the United States, the distribution of disease severity, and its impact on health-related quality of life. Among 1,278 participating adults (...) , the prevalence (95% confidence interval) of atopic dermatitis was 7.3% (5.9-8.8). Overall, 60.1% (56.1-64.1) of participants were classified as having mild, 28.9% (25.3-32.7) as having moderate, and 11% as having severe (8.6-13.7) disease. Patients with atopic dermatitis and those with more severe disease had higher scores in the dermatology life quality index (mean [standard deviation] for AD patients = 4.71 [6.44] vs. control individuals = 0.97 [2.12]) (P < 0.001) and the hospital anxiety (mean [standard

Full Text available with Trip Pro

2018 Journal of Investigative Dermatology

18. Report from the National Institute of Allergy and Infectious Diseases Workshop on "Atopic Dermatitis and the Atopic March: Mechanisms and Interventions". (PubMed)

Report from the National Institute of Allergy and Infectious Diseases Workshop on "Atopic Dermatitis and the Atopic March: Mechanisms and Interventions". Atopic dermatitis (AD) affects up to 20% of children worldwide and is an increasing public health problem, particularly in developed countries. Although AD in infants and young children can resolve, there is a well-recognized increased risk of sequential progression from AD to other atopic diseases, including food allergy (FA), allergic (...) rhinitis, allergic asthma, and allergic rhinoconjunctivitis, a process referred to as the atopic march. The mechanisms underlying the development of AD and subsequent progression to other atopic comorbidities, particularly FA, are incompletely understood and the subject of intense investigation. Other major research objectives are the development of effective strategies to prevent AD and FA, as well as therapeutic interventions to inhibit the atopic march. In 2017, the Division of Allergy, Immunology

2019 Journal of Allergy and Clinical Immunology

19. Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real life practice. (PubMed)

Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real life practice. Dupilumab has demonstrated efficacy in atopic dermatitis (AD)1-3 , asthma4 , perennial allergic rhinitis5 and chronic sinusitis6 . The objectives of this prospective observational, single-centre study were to assess 1) dupilumab efficacy in real-life practice and 2) the evolution of atopic co-morbidities and specific immunoglobulin E (IgE) levels during dupilumab treatment. This article

2019 British Journal of Dermatology

20. Immune dysregulation and Th2 polarization are associated with atopic dermatitis in heart-transplant children: A delicate balance between risk of rejection or atopic symptoms. (PubMed)

Immune dysregulation and Th2 polarization are associated with atopic dermatitis in heart-transplant children: A delicate balance between risk of rejection or atopic symptoms. Atopic dermatitis (AD) has a high incidence in heart-transplant children, and the reason why there is more AD after transplantation is still unknown. We conducted a cross-sectional study comparing 11 AD and 11 non-AD age-matched heart-transplant children, to assess which immune alterations are related to AD (...) understanding of atopic disorders in transplanted children.© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.

2019 American Journal of Transplantation

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>